Report cover image

Global PD-1 and PD-L1 Inhibitors Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Feb 08, 2025
Length 109 Pages
SKU # APRC19835001

Description

Summary

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

According to APO Research, The global PD-1 and PD-L1 Inhibitors market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of PD-1 and PD-L1 Inhibitors include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Inhibitors.

The PD-1 and PD-L1 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (L) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-1 and PD-L1 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

PD-1 and PD-L1 Inhibitors Segment by Company

Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA

PD-1 and PD-L1 Inhibitors Segment by Type

PD-1 Inhibitors
PD-L1 Inhibitors

PD-1 and PD-L1 Inhibitors Segment by Application

Solid Tumors
Blood-related Tumors

PD-1 and PD-L1 Inhibitors Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of PD-1 and PD-L1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

109 Pages
1 Market Overview

1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global PD-1 and PD-L1 Inhibitors Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts (2020-2031)
1.3 PD-1 and PD-L1 Inhibitors Market by Type
1.3.1 PD-1 Inhibitors
1.3.2 PD-L1 Inhibitors
1.4 Global PD-1 and PD-L1 Inhibitors Market Size by Type
1.4.1 Global PD-1 and PD-L1 Inhibitors Market Size Overview by Type (2020-2031)
1.4.2 Global PD-1 and PD-L1 Inhibitors Historic Market Size Review by Type (2020-2025)
1.4.3 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
1.5.2 Europe PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
1.5.4 South America PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics

2.1 PD-1 and PD-L1 Inhibitors Industry Trends
2.2 PD-1 and PD-L1 Inhibitors Industry Drivers
2.3 PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
2.4 PD-1 and PD-L1 Inhibitors Industry Restraints
3 Market Competitive Landscape by Company

3.1 Global Top Players by PD-1 and PD-L1 Inhibitors Revenue (2020-2025)
3.2 Global Top Players by PD-1 and PD-L1 Inhibitors Sales (2020-2025)
3.3 Global Top Players by PD-1 and PD-L1 Inhibitors Price (2020-2025)
3.4 Global PD-1 and PD-L1 Inhibitors Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global PD-1 and PD-L1 Inhibitors Major Company Production Sites & Headquarters
3.6 Global PD-1 and PD-L1 Inhibitors Company, Product Type & Application
3.7 Global PD-1 and PD-L1 Inhibitors Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global PD-1 and PD-L1 Inhibitors Market CR5 and HHI
3.8.2 Global Top 5 and 10 PD-1 and PD-L1 Inhibitors Players Market Share by Revenue in 2024
3.8.3 2023 PD-1 and PD-L1 Inhibitors Tier 1, Tier 2, and Tier 3
4 PD-1 and PD-L1 Inhibitors Regional Status and Outlook

4.1 Global PD-1 and PD-L1 Inhibitors Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global PD-1 and PD-L1 Inhibitors Historic Market Size by Region
4.2.1 Global PD-1 and PD-L1 Inhibitors Sales in Volume by Region (2020-2025)
4.2.2 Global PD-1 and PD-L1 Inhibitors Sales in Value by Region (2020-2025)
4.2.3 Global PD-1 and PD-L1 Inhibitors Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Region
4.3.1 Global PD-1 and PD-L1 Inhibitors Sales in Volume by Region (2026-2031)
4.3.2 Global PD-1 and PD-L1 Inhibitors Sales in Value by Region (2026-2031)
4.3.3 Global PD-1 and PD-L1 Inhibitors Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 PD-1 and PD-L1 Inhibitors by Application

5.1 PD-1 and PD-L1 Inhibitors Market by Application
5.1.1 Solid Tumors
5.1.2 Blood-related Tumors
5.2 Global PD-1 and PD-L1 Inhibitors Market Size by Application
5.2.1 Global PD-1 and PD-L1 Inhibitors Market Size Overview by Application (2020-2031)
5.2.2 Global PD-1 and PD-L1 Inhibitors Historic Market Size Review by Application (2020-2025)
5.2.3 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
5.3.2 Europe PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
5.3.4 South America PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
6 Company Profiles

6.1 Merck
6.1.1 Merck Comapny Information
6.1.2 Merck Business Overview
6.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
6.1.5 Merck Recent Developments
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Comapny Information
6.2.2 Bristol-Myers Squibb Business Overview
6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments
6.3 Roche
6.3.1 Roche Comapny Information
6.3.2 Roche Business Overview
6.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
6.3.5 Roche Recent Developments
6.4 AstraZeneca
6.4.1 AstraZeneca Comapny Information
6.4.2 AstraZeneca Business Overview
6.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
6.4.5 AstraZeneca Recent Developments
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Comapny Information
6.5.2 Ono Pharmaceutical Business Overview
6.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments
6.6 Regeneron
6.6.1 Regeneron Comapny Information
6.6.2 Regeneron Business Overview
6.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
6.6.5 Regeneron Recent Developments
6.7 Innovent
6.7.1 Innovent Comapny Information
6.7.2 Innovent Business Overview
6.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
6.7.5 Innovent Recent Developments
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Comapny Information
6.8.2 Hengrui Medicine Business Overview
6.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
6.8.5 Hengrui Medicine Recent Developments
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Comapny Information
6.9.2 Junshi Biosciences Business Overview
6.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
6.9.5 Junshi Biosciences Recent Developments
6.10 Merck KGaA
6.10.1 Merck KGaA Comapny Information
6.10.2 Merck KGaA Business Overview
6.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
6.10.5 Merck KGaA Recent Developments
7 North America by Country

7.1 North America PD-1 and PD-L1 Inhibitors Sales by Country
7.1.1 North America PD-1 and PD-L1 Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America PD-1 and PD-L1 Inhibitors Sales by Country (2020-2025)
7.1.3 North America PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2026-2031)
7.2 North America PD-1 and PD-L1 Inhibitors Market Size by Country
7.2.1 North America PD-1 and PD-L1 Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America PD-1 and PD-L1 Inhibitors Market Size by Country (2020-2025)
7.2.3 North America PD-1 and PD-L1 Inhibitors Market Size Forecast by Country (2026-2031)
8 Europe by Country

8.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country
8.1.1 Europe PD-1 and PD-L1 Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2020-2025)
8.1.3 Europe PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2026-2031)
8.2 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
8.2.1 Europe PD-1 and PD-L1 Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe PD-1 and PD-L1 Inhibitors Market Size by Country (2020-2025)
8.2.3 Europe PD-1 and PD-L1 Inhibitors Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country

9.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales by Country
9.1.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2020-2025)
9.1.3 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Market Size by Country
9.2.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Market Size by Country (2020-2025)
9.2.3 Asia-Pacific PD-1 and PD-L1 Inhibitors Market Size Forecast by Country (2026-2031)
10 South America by Country

10.1 South America PD-1 and PD-L1 Inhibitors Sales by Country
10.1.1 South America PD-1 and PD-L1 Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America PD-1 and PD-L1 Inhibitors Sales by Country (2020-2025)
10.1.3 South America PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2026-2031)
10.2 South America PD-1 and PD-L1 Inhibitors Market Size by Country
10.2.1 South America PD-1 and PD-L1 Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America PD-1 and PD-L1 Inhibitors Market Size by Country (2020-2025)
10.2.3 South America PD-1 and PD-L1 Inhibitors Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country

11.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country
11.1.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2020-2025)
11.1.3 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country
11.2.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country (2020-2025)
11.2.3 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis

12.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
12.1.1 PD-1 and PD-L1 Inhibitors Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 PD-1 and PD-L1 Inhibitors Production Mode & Process
12.2 PD-1 and PD-L1 Inhibitors Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 PD-1 and PD-L1 Inhibitors Distributors
12.2.3 PD-1 and PD-L1 Inhibitors Customers
13 Concluding Insights
14 Appendix

14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us